{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:27:08Z","timestamp":1792211228480,"version":"4.4.0"},"reference-count":48,"publisher":"The Journal of Rheumatology","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2010,11]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>It is unclear if skin cancer risk is affected by the use of immunomodulatory medications in rheumatoid arthritis (RA), psoriasis, and psoriatic arthritis (PsA). The purpose of this study is to evaluate and summarize the available data pertinent to this question.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>The English language literature on PubMed was searched with a combination of phrases, including \u201cmalignancy,\u201d \u201cskin cancer,\u201d \u201csquamous cell carcinoma,\u201d \u201cbasal cell carcinoma,\u201d \u201cmelanoma,\u201d \u201cpsoriasis,\u201d \u201cpsoriatic arthritis,\u201d and \u201crheumatoid arthritis\u201d in addition to the generic names of a variety of common immunomodulatory drugs. Relevant articles were identified and data were extracted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>In total, 2218 potentially relevant articles were identified through the search process. After further screening, 20 articles relevant to RA were included. An additional 19 articles relevant to either psoriasis or PsA were included as well. RA may be a risk factor for the development of cutaneous malignancy. Treatment with tumor necrosis factor inhibitors increases the rates of non-melanoma skin cancer (NMSC) in RA and psoriasis. This risk doubles when combination methotrexate therapy is used in RA. Methotrexate may increase the risk of malignant melanoma in patients with RA and the risk of NMSC in psoriasis. Cyclosporine and prior phototherapy significantly increase the risk of NMSC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>RA may potentiate the risk of cutaneous malignancy and therefore dermatologic screening in this population should be considered. The use of immunomodulatory therapy in RA, psoriasis, and PsA may further increase the risk of cutaneous malignancy and therefore dermatologic screening examinations are warranted in these groups. More careful recording of skin cancer development during clinical trials and cohort studies is necessary to further delineate the risks of immunomodulatory therapy.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.100041","type":"journal-article","created":{"date-parts":[[2010,9,2]],"date-time":"2010-09-02T01:01:20Z","timestamp":1283389280000},"page":"2205-2215","source":"Crossref","is-referenced-by-count":57,"title":["Pharmacologic Immunomodulation and Cutaneous Malignancy in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis"],"prefix":"10.3899","volume":"37","author":[{"given":"MICHAEL S.","family":"KRATHEN","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ALICE B.","family":"GOTTLIEB","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PHILIP J.","family":"MEASE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2010,9,1]]},"reference":[{"key":"2018112909250894000_37.11.2205.1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2010.4"},{"key":"2018112909250894000_37.11.2205.2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.186"},{"key":"2018112909250894000_37.11.2205.3","unstructured":"American Cancer Society, Cancer Facts & Figures 2009. Atlanta: American Cancer Society; 2009. [Internet. Accessed July 8, 2010.] Available from: http:\/\/www.cancer.org\/docroot\/STT\/STT_0.asp"},{"key":"2018112909250894000_37.11.2205.4","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2007-0251"},{"key":"2018112909250894000_37.11.2205.5","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.099861"},{"key":"2018112909250894000_37.11.2205.6","first-page":"116","article-title":"Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial","volume":"158","author":"Flytstrom","year":"2008","journal-title":"Br J Dermatol"},{"key":"2018112909250894000_37.11.2205.7","first-page":"2274","article-title":"A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis","volume":"28","author":"Salvarani","year":"2001","journal-title":"J Rheumatol"},{"key":"2018112909250894000_37.11.2205.8","doi-asserted-by":"crossref","unstructured":"Nash P Clegg DO . Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis 2005;64 Suppl 2:ii74\u20137.","DOI":"10.1136\/ard.2004.030783"},{"key":"2018112909250894000_37.11.2205.9","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2036.2007.03455.x","article-title":"Medical management of mild to moderate Crohn\u2019s disease: evidence-based treatment algorithms for induction and maintenance of remission","volume":"26","author":"Sandborn","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"2018112909250894000_37.11.2205.10","first-page":"2130","article-title":"Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors","volume":"32","author":"Chakravarty","year":"2005","journal-title":"J Rheumatol"},{"key":"2018112909250894000_37.11.2205.11","doi-asserted-by":"publisher","DOI":"10.1002\/art.24941"},{"key":"2018112909250894000_37.11.2205.12","doi-asserted-by":"publisher","DOI":"10.1002\/art.23716"},{"key":"2018112909250894000_37.11.2205.13","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.033993"},{"key":"2018112909250894000_37.11.2205.14","doi-asserted-by":"publisher","DOI":"10.1002\/art.22864"},{"key":"2018112909250894000_37.11.2205.15","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/0002-9343(85)90245-1","article-title":"Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment","volume":"78","author":"Kinlen","year":"1985","journal-title":"Am J Med"},{"key":"2018112909250894000_37.11.2205.16","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.141.7.861"},{"key":"2018112909250894000_37.11.2205.17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.19.2275"},{"key":"2018112909250894000_37.11.2205.18","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.094904"},{"key":"2018112909250894000_37.11.2205.19","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.102103"},{"issue":"Suppl II","key":"2018112909250894000_37.11.2205.20","first-page":"322","article-title":"Malignancies from patients receiving etanercept across approved indications [abstract]","volume":"67","author":"Gottlieb","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2018112909250894000_37.11.2205.21","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.038349"},{"key":"2018112909250894000_37.11.2205.22","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.099218"},{"key":"2018112909250894000_37.11.2205.23","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.074773"},{"key":"2018112909250894000_37.11.2205.24","doi-asserted-by":"publisher","DOI":"10.1002\/art.22070"},{"key":"2018112909250894000_37.11.2205.25","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.097527"},{"key":"2018112909250894000_37.11.2205.26","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090856"},{"key":"2018112909250894000_37.11.2205.27","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1365-4362.1989.tb02534.x","article-title":"Risk factors for basal cell carcinoma","volume":"28","author":"Hogan","year":"1989","journal-title":"Int J Dermatol"},{"key":"2018112909250894000_37.11.2205.28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1986.tb05767.x"},{"key":"2018112909250894000_37.11.2205.29","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.02655.x"},{"key":"2018112909250894000_37.11.2205.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.06.016"},{"key":"2018112909250894000_37.11.2205.31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03093.x"},{"key":"2018112909250894000_37.11.2205.32","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2003.12040.x"},{"key":"2018112909250894000_37.11.2205.33","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.136.12.1524"},{"key":"2018112909250894000_37.11.2205.34","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0360"},{"key":"2018112909250894000_37.11.2205.35","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19940601)73:11<2759::AID-CNCR2820731118>3.0.CO;2-C"},{"key":"2018112909250894000_37.11.2205.36","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12506290"},{"key":"2018112909250894000_37.11.2205.37","doi-asserted-by":"publisher","DOI":"10.1080\/09546630701846103"},{"key":"2018112909250894000_37.11.2205.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2005.12.007"},{"key":"2018112909250894000_37.11.2205.39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60140-9"},{"key":"2018112909250894000_37.11.2205.40","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60725-4"},{"key":"2018112909250894000_37.11.2205.41","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60726-6"},{"key":"2018112909250894000_37.11.2205.42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810652"},{"key":"2018112909250894000_37.11.2205.43","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-0172(99)80026-2"},{"key":"2018112909250894000_37.11.2205.44","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(95)91393-9"},{"key":"2018112909250894000_37.11.2205.45","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1996.03890300039008"},{"key":"2018112909250894000_37.11.2205.46","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000249793","article-title":"Frequency of malignant neoplasms in 248 long-term methotrexate-treated psoriatics. A preliminary study","volume":"167","author":"Nyfors","year":"1983","journal-title":"Dermatologica"},{"key":"2018112909250894000_37.11.2205.47","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2000.00898.x"},{"key":"2018112909250894000_37.11.2205.48","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19820901)50:5<869::AID-CNCR2820500511>3.0.CO;2-V"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.100041","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T04:26:55Z","timestamp":1559536015000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.100041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,1]]},"references-count":48,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2010,11,1]]},"published-print":{"date-parts":[[2010,11]]}},"alternative-id":["10.3899\/jrheum.100041"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.100041","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,1]]}}}